Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
Axcelead and Teijin hope to discover novel compounds through their joint venture Axcelead Tokyo West Partners launched this April by creating synergies in their overlapping focus disease areas while extending each other’s competitive edge in other fields. The JV, owned…
To read the full story
Related Article
- Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
- Teijin, Axcelead Seal Definitive Accord to Form Drug Discovery JV
July 4, 2023
- Teijin, Axcelead to Launch Drug Discovery Joint Venture
February 22, 2023
BUSINESS
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…